Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

60
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
60
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

32
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
32
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

92
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
92
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

536
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
536
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

67
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
67
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

54
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
54

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

Annals of the rheumatic diseases·2026
Same author

Beyond renal response: sustained systemic disease control protects against adverse long-term outcomes in lupus nephritis.

Lupus science & medicine·2026
Same author

Treat-to-target in Behçet syndrome.

Nature reviews. Rheumatology·2026
Same author

Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study.

RMD open·2026
Same author

Difficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome.

Arthritis research & therapy·2026
Same author

DNA damage in macrophages drives immune autoreactivity via nuclear antigen presentation.

Nature aging·2026

Related Experiment Video

Updated: Sep 25, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.1K

Lupus Nephritis: Improving Treatment Options.

Myrto Kostopoulou1, Sofia Pitsigavdaki2, George Bertsias3,4

  • 1Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Drugs
|April 29, 2022
PubMed
Summary

New lupus nephritis treatments show promise but require personalized approaches. Close monitoring and prompt, deep responses are crucial for long-term kidney function preservation in lupus nephritis patients.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

558
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.9K

Related Experiment Videos

Last Updated: Sep 25, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.1K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

558
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.9K

Area of Science:

  • Nephrology
  • Immunology
  • Rheumatology

Background:

  • Despite advancements, many lupus nephritis patients experience suboptimal responses, relapses, and organ damage.
  • Glucocorticoid use and its associated toxicities remain a concern in lupus nephritis management.

Purpose of the Study:

  • To review current lupus nephritis management recommendations.
  • To critically appraise recent clinical trials of novel therapeutic agents.
  • To discuss the potential role of new treatments in achieving treat-to-target goals.

Main Methods:

  • Systematic review of existing lupus nephritis guidelines.
  • Critical appraisal of randomized controlled trials for belimumab and voclosporin.
  • Review of emerging data on other investigational compounds like obinutuzumab.

Main Results:

  • Belimumab and voclosporin, in combination with conventional therapies, demonstrate potential for improved outcomes and faster steroid tapering.
  • Uncertainty remains regarding the optimal patient subgroups for these dual regimens as first-line therapy.

Conclusions:

  • Personalized treatment decisions for lupus nephritis are needed, guided by predictive biomarkers.
  • Close patient monitoring and timely treatment adjustments are essential for achieving deep responses and preserving kidney function.